Generate Biomedicines, a Somerville-based company specializing in AI-driven drug development, has completed a $400 million initial public offering (IPO). The offering matches the record for the largest biotech IPO set in 2020, signaling renewed activity in the sector after a period of limited public offerings. The company’s successful entry into the public markets is being…
